News

Kerri Aronson, MD, MS, describes her team's research efforts to create educational resources that address the profound lack of patient knowledge around HP.

After his review on recent literature, Zirwas’s Maui Derm NP+PA Fall interview featured a discussion about the biggest unmet needs among patients.

The IL-23 inhibitor lowered the risk of uveitis more than TNF-α inhibitors in patients with moderate to severe psoriasis.

The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.

A report shows only 24%, 56%, and 62% of patients meet the criteria PSIL-AT for depression according to low-bound, mid-range, and upper-bound estimates, respectively.

At Maui Derm NP+PA Fall 2024, bimekizumab data demonstrates a consistent safety profile in moderate to severe plaque psoriasis over 4 years, with decreasing event rates over time.

This interview featured a literature review discussion about non-FDA approved advancements in dermatology, including oral roflumilast for psoriasis, metformin for acne, and minoxidil for nails.

Moser reviews ongoing unmet needs in PBC and how the addition of 2 new second-line treatment options has changed the treatment landscape.

In this interview segment, Chovatiya highlights HS therapies such as IL-17 inhibitors and JAK inhibitors, as well as unmet needs of patients.

This interview with Chovatiya highlights promising therapies in the dermatology space for the treatment of patients with the skin condition HS.

Mathew emphasizes the importance of routine liver cancer screening in patients with advanced liver disease and the need to overcome insurance barriers for HCC panel testing.

Gildeuretinol showed a clinically meaningful reduction in geographic atrophy lesion growth and a favorable safety profile at 24 months in the Phase 3 SAGA trial.

Leo Pharma announced the availability of a single-dose autoinjector of tralokinumab for moderate-to-severe atopic dermatitis, approved by the FDA in June 2024.

Iordache emphasizes the importance of a multidisciplinary approach to liver disease care in pregnant patients and the need for patient education.

Here's what to expect from the new pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

In this Maui Derm fall conference session, Callender highlights approaches to pigmentation issues such as vitiligo, melasma, and other disorders.

People living with HP generally experience a profound lack of knowledge about their disease, driving poorer health-related quality of life. A study sought to create educational resources to curb this effect.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

These poster data highlight that atopic dermatitis treatment may be suboptimal in certain patients, demonstrating the necessity of additional effective therapy options.

Nemolizumab shows early and sustained benefits in reducing itch and sleep disturbance in moderate-to-severe atopic dermatitis, per ARCADIA data.

A new study found glucagon-like peptide 1 receptor agonist use was associated with a lower risk of cirrhosis complications for patients with MASLD who did not have cirrhosis.

The Medical Sisterhood, hosted by Mona Shahriari, MD, is the latest multimedia program from HCPLive Dermatology!

Legaspi reviews different treatment options for managing ascites, ranging from limiting dietary sodium intake to diuretic use and therapeutic paracentesis.

These real-world data resulted from an interim analysis of the PSoSA study on psoriasis patients with scalp itch, nail pain, and quality of life impairment.

Franco describes the importance of discussing pregnancy intentions with patients with liver disease and the need for multidisciplinary comanagement of these patients.

The FDA advises stopping the fezolinetant treatment at the first signs of liver injury to prevent further damage and help restore normal liver function.

Mathew reviews common reasons for diagnostic delays in PBC, emphasizing the importance of timely identification and prompt treatment for improving patient outcomes.

Wilson details how her team plans to develop risk assessment models to estimate respiratory viral infection risk reductions for interventions in elementary schools.